Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zinzani, P.
Right arrow Articles by Tura, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P.
Right arrow Articles by Tura, S
Haematologica, Vol 81, Issue 2, 168-171
Copyright © 1996 by Ferrata Storti Foundation

Clinical Trial

FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma

PL Zinzani, M Bendandi, F Gherlinzoni, E Merla, A Gozzetti, and S Tura

Institute of Hematology Seragnoli, University of Bologna, Italy.

Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising activity in lymphoproliferative disorders and, in particular, in low-grade non-Hodgkin's lymphoma (LG-NHL). Recently, a few reports have described interesting results using FLU in polychemotherapy regimens. In order to evaluate FLU in combination with other antineoplastic agents, we used a combination of FLU and idarubicin, called the FLU-ID regimen, to treat 10 patients with recurrent LG-NHL. The FLU-ID regimen was as follows: FLU 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12 mg/sqm i.v. on day 1. Of the 10 patients, 2 (20%) achieved complete response (CR), 5 (50%) partial response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in remission after 6 and 8 months, respectively. The median duration of overall survival of all patients was 8 months. The major toxic effects observed were neutropenia (40%) and infections and/or febrile episodes (15%); no fatalities due to drug side effects occurred. These results indicate the efficacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recurrent LG-NHL.


This article has been cited by other articles:


Home page
 JCOHome page
P. L. Zinzani, M. Magagnoli, L. Moretti, A. De Renzo, R. Battista, A. Zaccaria, L. Guardigni, P. Mazza, R. Marra, F. Ronconi, et al.
Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma
J. Clin. Oncol., February 14, 2000; 18(4): 773 - 773.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Papamichael, A. J. Norton, J. M. Foran, C. Mulatero, J. Mathews, J. A.L Amess, M. Bradburn, T. A. Lister, and A. Z.S. Rohatiner
Immunocytoma: A Retrospective Analysis From St Bartholomew's Hospital1972 to 1996
J. Clin. Oncol., September 1, 1999; 17(9): 2847 - 2847.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1996 by the Ferrata Storti Foundation.